Noscira SA   Report issue

For profit Phase 2
Founded: Madrid Spain (2000)
Status: Defunct (2016)

Organization Overview

First Clinical Trial
2008
NCT00948259
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

tideglusib (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1